维奈克拉治疗急性淋巴细胞白血病的研究进展  

Recent advances in the treatment of acute lymphoblastic leukemia with Venetoclax

作　　者：米浩 孙道萍[2] MI Hao;SUN Daoping(Clinical Medical College of Jining Medical College,Jining,272000,China;Department of Hematology,Jining First People's Hospital)

机构地区：[1]济宁医学院临床医学院,山东济宁272000 [2]济宁市第一人民医院血液科

出　　处：《临床血液学杂志》2024年第11期830-833,838,共5页Journal of Clinical Hematology

摘　　要：维奈克拉是一种新型口服BCL-2抑制剂,在临床前和早期临床研究中显示出对多种血液恶性肿瘤和实体瘤的疗效,目前已被FDA批准用于慢性淋巴细胞白血病和急性髓系白血病的治疗。研究证实维奈克拉对急性淋巴细胞白血病也具有一定疗效,但单药作用有限。多项临床试验表明维奈克拉与不同药物联合治疗复发或难治性急性淋巴细胞白血病安全、有效,并可作为造血干细胞移植的桥接治疗,具有一定的应用前景,但仍需更多临床数据的支持。Venetoclax is a novel oral BCL-2 inhibitor that has been approved by the FDA for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia.It has been shown to be effective in a variety of hematological malignancies and solid tumors in preclinical and early clinical studies.Studies have confirmed that Venetoclax also has a certain effect on acute lymphoblastic leukemia,but the effect of a single drug is limited.A number of clinical trials have shown that the combination of Venetoclax and different drugs is safe and effective in the treatment of relapsed or refractory acute lymphoblastic leukemia,and can be used as a bridging treatment for hematopoietic stem cell transplantation.It has certain application prospects,but it still needs more clinical data to support.

关 键 词：BCL-2抑制剂 急性淋巴细胞白血病 维奈克拉 

分 类 号：R733.71[医药卫生—肿瘤]